Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Trial Identifier: D7680C00001
Sponsor: AstraZeneca
NCTID:: NCT06192004
Start Date: January 2024
Primary Completion Date: June 2025
Study Completion Date: June 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
USA, California Los Angeles, California, USA, 90027
USA, Colorado Denver, Colorado, USA, 80222
USA, Illinois Skokie, Illinois, USA, 60076
USA, Michigan Troy, Michigan, USA, 48098
USA, New Jersey Mickleton, New Jersey, USA, 08056
USA, New York Westbury, New York, USA, 11590
USA, Ohio Canton, Ohio, USA, 44710
USA, Ohio Canton, Ohio, USA, 44708
USA, Ohio Massillon, Ohio, USA, 44646
USA, Texas Austin, Texas, USA, 78745
USA, Texas Dallas, Texas, USA, 75246
USA, Texas El Paso, Texas, USA, 79902
USA, Texas Houston, Texas, USA, 77024
USA, Texas Longview, Texas, USA, 75601